close

  • home Home

  • linked_services Solutions keyboard_arrow_down

    • biotech Core Disciplines keyboard_arrow_down

      • View All
      • Quality Control
      • EQA
      • Chemistry
      • Immunoassay
      • Molecular
      • Point of Care
      • Toxicology
      • Food Diagnostics
      • BioSciences
      • BioReagents
      • Veterinary

    • neurology Disease Areas keyboard_arrow_down

      • View All
      • Acute Kidney Injury
      • Alzheimer's Disease
      • Chronic Kidney Disease
      • Chronic Lung Infection
      • Colorectal Cancer
      • Familial Hypercholesterolemia
      • Gastrointestinal
      • Hyperinflammation
      • Immunodeficiency
      • Neurovascular Dysfunction
      • Pancreatic Cancer
      • Urinary Tract Infection
      • Female Bladder Cancer Array
      • Acute Respiratory Distress Syndrome (ARDS)

    • store Online Store

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

    • Our Story
    • Our Vision
    • Our Team
    • Partners & Sponsorships
    • Charity Partners
    • Collaborators
    • Careers

  • mail Contact

  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu
Randox Health search

Get in touch to discover more

To find out more about the Acute Respiratory Distress, enquire now.

Make an Enquiry mail
download Download brochure

humidity_low Sample Type:
Plasma

update Time to Result:
36 Minutes

Studies have shown that clinicians can improve patient survival rates in acute respiratory distress syndrome (ARDS) by distinguishing between two consistently identified phenotypes.

It is crucial to identify the hyperinflammatory phenotype quickly so that the clinician can make informed decisions regarding patient management options, which are essential in improving survival. The Evidence MultiSTAT ARDS Biochip* allows for fast and accurate detection of Interleukin-6 (IL-6) and Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1), enabling the stratification of the ARDS phenotypes.

*Used in conjunction with blood gas assay and algorithm

Biochip Performance

BiomarkerMeasuring Range
Biomarker: Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1)Measuring Range: 0 - 25 ng/mL
Biomarker: Interleukin-6 (IL-6)Measuring Range: 0 - 1600 pg/mL
acute Fast & Accurate Detection

Fast and accurate detection of biomarkers to facilitate stratification of ARDS patients into hypo and hyper-inflammatory phenotypes.

timer_3 Simple Operator Process

Analyser can be used by suitably qualified personnel to quickly analyse patient samples and obtain easily comprehensible results in just three simple steps.

hub Rapid Stratification

Rapid stratification compared to other lab-based biomarker testing facilitating a precision medicine approach in ARDS patients.

update Results in 36 Minutes

Prompt reporting time to results enables faster treatment plans for patients.

The Evidence MultiSTAT

The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.

Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.

With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.

MultiSTAT brochure  download

MultiSTAT Cartridge

The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.

The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.

No other components are required.